Cargando…

Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease

BACKGROUND: Increased circulatory levels of the chemokine CXCL4 have been associated with the presence of interstitial lung disease (ILD) in an observational study of patients with systemic sclerosis (SSc). The purpose of the present study was to evaluate the relationship between baseline CXCL4 leve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Volkmann, Elizabeth R., Tashkin, Donald P., Roth, Michael D., Clements, Philip J., Khanna, Dinesh, Furst, Daniel E., Mayes, Maureen, Charles, Julio, Tseng, Chi-Hong, Elashoff, Robert M., Assassi, Shervin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203703/ https://www.ncbi.nlm.nih.gov/pubmed/28038680 http://dx.doi.org/10.1186/s13075-016-1203-y

Ejemplares similares

Racial Disparities in Systemic Sclerosis: Short‐ and Long‐Term Outcomes Among African American Participants of SLS I and II
por: Volkmann, Elizabeth R., et al.
Publicado: (2020)

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials
por: Khanna, Dinesh, et al.
Publicado: (2015)

Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease
por: Assassi, Shervin, et al.
Publicado: (2022)

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
por: Khanna, Dinesh, et al.
Publicado: (2019)

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
por: Volkmann, Elizabeth R., et al.
Publicado: (2020)

Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study
por: Assassi, Shervin, et al.
Publicado: (2022)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease
por: Khanna, Dinesh, et al.
Publicado: (2020)

The Effect of Anti‐Scl‐70 Antibody Determination Method on Its Predictive Significance for Interstitial Lung Disease Progression in Systemic Sclerosis
por: Jandali, Bochra, et al.
Publicado: (2022)

Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial
por: Tashkin, Donald P, et al.
Publicado: (2016)

Predictors of progression in systemic sclerosis patients with interstitial lung disease
por: Distler, Oliver, et al.
Publicado: (2020)

Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease
por: Khanna, Dinesh, et al.
Publicado: (2019)

Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort
por: Assassi, Shervin, et al.
Publicado: (2010)

Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy
por: Volkmann, Elizabeth R., et al.
Publicado: (2023)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
por: Rahaghi, Franck F., et al.
Publicado: (2023)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial
por: Volkmann, Elizabeth R, et al.
Publicado: (2022)

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Maher, Toby M., et al.
Publicado: (2021)

Computed Tomography of the Chest to Screen for Interstitial Lung Disease in Patients With Systemic Sclerosis at Expert Scleroderma Centers in the United States
por: Bernstein, Elana J., et al.
Publicado: (2022)

Enrichment Strategy for Systemic Sclerosis Clinical Trials Targeting Skin Fibrosis: A Prospective, Multiethnic Cohort Study
por: Mihai, Carina, et al.
Publicado: (2020)

Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention
por: Fischer, Aryeh, et al.
Publicado: (2019)

Genetics of scleroderma: implications for personalized medicine?
por: Assassi, Shervin, et al.
Publicado: (2013)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Early Radiographic Progression of Scleroderma: Lung Disease Predicts Long-term Mortality
por: Volkmann, Elizabeth R., et al.
Publicado: (2022)

CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases–associated interstitial lung disease and interstitial pneumonia with autoimmune features
por: Kameda, Masami, et al.
Publicado: (2020)

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
por: Assassi, Shervin, et al.
Publicado: (2022)

Augmented concentrations of CX(3)CL1 are associated with interstitial lung disease in systemic sclerosis
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2018)

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
por: Adler, Sabine, et al.
Publicado: (2018)

Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis
por: Khanna, Surabhi Agarwal, et al.
Publicado: (2022)

Successful treatment of telomeropathy‐related interstitial lung disease with immunosuppression and danazol
por: Chambers, Daniel C., et al.
Publicado: (2020)

Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit
por: Kakkar, Vishal, et al.
Publicado: (2022)

Correction to: Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis
por: Khanna, Surabhi Agarwal, et al.
Publicado: (2022)

Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
por: Zhang, David, et al.
Publicado: (2023)

Multiomic study of skin, peripheral blood, and serum: is serum proteome a reflection of disease process at the end-organ level in systemic sclerosis?
por: Farutin, Victor, et al.
Publicado: (2021)

Protein biomarkers of disease progression in patients with systemic sclerosis associated interstitial lung disease
por: Cerro-Chiang, Giuliana, et al.
Publicado: (2023)

Osteopontin in Systemic Sclerosis and its Role in Dermal Fibrosis
por: Wu, Minghua, et al.
Publicado: (2012)

Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients
por: Wu, Minghua, et al.
Publicado: (2016)

Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression
por: Dias, Vitor Loureiro, et al.
Publicado: (2022)

Prevalence of latent tuberculosis infection among patients with interstitial lung disease requiring immunosuppression
por: Kempisty, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kljdatha5ovnhvv5vb3f7p8eu6